Evidence map›Paper›PMID 27314585›Full record

ArticlePloS one2016

Genetic Characterization of a Panel of Diverse HIV-1 Isolates at Seven International Sites.

Bhavna Hora, Sheila M Keating, Yue Chen, Ana M Sanchez, Ester Sabino, Gillian Hunt, Johanna Ledwaba, John Hackett, Priscilla Swanson, Indira Hewlett and 11 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Plasma CD16mBio · 2022
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 6 countries.

Bhavna HoraDuke Human Vaccine Institute and Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.
Sheila M KeatingBlood Systems Research Institute, San Francisco, California, United States of America.
Yue ChenDuke Human Vaccine Institute and Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.
Ana M SanchezDuke Human Vaccine Institute and Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.
Ester SabinoInstituto de Medicina Tropical, Sao Paolo Brazil.
Gillian HuntNational Institute of Communicable Diseases, Johannesburg, South Africa.
Johanna LedwabaNational Institute of Communicable Diseases, Johannesburg, South Africa.
John HackettAbbott Laboratories, Infectious Diseases Research, Abbott Park, Illinois, United States of America.
Priscilla SwansonAbbott Laboratories, Infectious Diseases Research, Abbott Park, Illinois, United States of America.
Indira HewlettCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Springs, Maryland, United States of America.
Viswanath RagupathyCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Springs, Maryland, United States of America.
Sai Vikram VemulaCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Springs, Maryland, United States of America.
Peibin ZengInstitute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China.
Kok-Keng TeeCentre of Excellence for Research in AIDS, Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Wei Zhen ChowCentre of Excellence for Research in AIDS, Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Hezhao JiNational HIV & Retrovirology Laboratories at JC Wilt Infectious Diseases Research Center, Public Health Agency of Canada, Winnipeg, Canada.
Paul SandstromNational HIV & Retrovirology Laboratories at JC Wilt Infectious Diseases Research Center, Public Health Agency of Canada, Winnipeg, Canada.
Thomas N DennyDuke Human Vaccine Institute and Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.
Michael P BuschBlood Systems Research Institute, San Francisco, California, United States of America.
Feng GaoDuke Human Vaccine Institute and Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.
REDS-III and EQAPOL programs
Duke Medical Center · USCenter for Biologics Evaluation and Research · USAbbott Fund · USPublic Health Agency of Canada · CARespiratory and Meningeal Pathogens Research Unit · ZAUniversity of Malaya · MYBlood Systems Research Institute · USChinese Academy of Medical Sciences & Peking Union Medical College · CNInstituto de Medicina Avançada · BRUniversity of California, San Francisco · US

Funding

NHLBI NIH HHS HHSN268201100001INHLBI NIH HHS HHSN268201100007CNHLBI NIH HHS HHSN268201100007INHLBI NIH HHS HHSN268201100009CNHLBI NIH HHS HHSN268201100009INIAID NIH HHS HHSN272200800014CNIAID NIH HHS HHSN272201000045CWHI NIH HHS HHSN268201100001C
6 · The paper itself

Abstract

HIV-1 subtypes and drug resistance are routinely tested by many international surveillance groups. However, results from different sites often vary. A systematic comparison of results from multiple sites is needed to determine whether a standardized protocol is required for consistent and accurate data analysis. A panel of well-characterized HIV-1 isolates (N = 50) from the External Quality Assurance Program Oversight Laboratory (EQAPOL) was assembled for evaluation at seven international sites. This virus panel included seven subtypes, six circulating recombinant forms (CRFs), nine unique recombinant forms (URFs) and three group O viruses. Seven viruses contained 10 major drug resistance mutations (DRMs). HIV-1 isolates were prepared at a concentration of 107 copies/ml and compiled into blinded panels. Subtypes and DRMs were determined with partial or full pol gene sequences by conventional Sanger sequencing and/or Next Generation Sequencing (NGS). Subtype and DRM results were reported and decoded for comparison with full-length genome sequences generated by EQAPOL. The partial pol gene was amplified by RT-PCR and sequenced for 89.4%-100% of group M viruses at six sites. Subtyping results of majority of the viruses (83%-97.9%) were correctly determined for the partial pol sequences. All 10 major DRMs in seven isolates were detected at these six sites. The complete pol gene sequence was also obtained by NGS at one site. However, this method missed six group M viruses and sequences contained host chromosome fragments. Three group O viruses were only characterized with additional group O-specific RT-PCR primers employed by one site. These results indicate that PCR protocols and subtyping tools should be standardized to efficiently amplify diverse viruses and more consistently assign virus genotypes, which is critical for accurate global subtype and drug resistance surveillance. Targeted NGS analysis of partial pol sequences can serve as an alternative approach, especially for detection of low-abundance DRMs.

Indexed as

High-Throughput Nucleotide SequencingDrug Resistance, ViralGenes, polGenotypeHIV-1HIV InfectionsHumansMolecular Sequence DataMutationPhylogenyRecombination, Genetic

Identifiers

PMID27314585
PMCPMC4912073
OpenAlexW2438122098

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.